𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of vinorelbine (VRL), cisplatin (CDDP) and 5-Fluorouracil (FU) in patients (PTS) with locally advanced recurrent, and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

✍ Scribed by V. Guillem; M.A. Muñoz; R. Yaya; V. Soriano; M.A. Climent; C. Gaspar

Book ID
117667641
Publisher
Elsevier Science
Year
1999
Tongue
English
Weight
142 KB
Volume
35
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of cisplatin and vinore
A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
✍ Enrique Espinosa; Pilar Zamora; Alfredo Millá; Serafin Morales; Raquel Molina; M 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Abstract ## Objective. We assessed the response rate and the toxicity of cisplatin plus vinorelbine in patients with this condition. ## Patients and Method. Forty‐two patients were included. Therapy consisted of cisplatin, 100 mg/m^2^ on day 1, and vinorelbine, 25 mg/m^2^ on days 1 and 8, giv

Paclitaxel, cisplatin, and 5-fluorouraci
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck
✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi